MedTechInvestment

Isomorphic Labs, an AI drug design company, has confirmed the close of its planned $5bn (£3.75bn) Series C funding round.

The round was co-led by Greenoaks and Sequoia Capital – the latter of which recently closed its UK office – alongside Andreessen Horowitz (a16z) and several other new investors.

Google’s parent company Alphabet continues to invest significantly in Isomorphic, which was founded by DeepMind founder Sir Demis Hassabis.

The round also included participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic Labs says it is focused on designing and developing new medicines with AI. The company said it is scaling its proprietary drug design engine, known as IsoDDE, and its therapeutic candidate pipeline designed with AI.

It says the aim is to deliver the next generation of medicines for patients, with first clinical trials expected to start before the end of the year.

Isomorphic raised £1.6bn in Series B funding just this summer, following a $600m round completed in March.

The company said the $5bn would accelerate the scientific breakthroughs and proprietary AI advances being made by Isomorphic.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” said Sir Demis. “Our drug design engine is generating molecules with unprecedented precision and speed.

“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

Max Jaderberg, president of Isomorphic Labs, added: “Every week we are making repeatable scientific advancements enabled by our models. These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery.

“Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades.

“We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.”

Maven backs newly founded Syntric Group with up to £50m

Neil Mehta, founder and managing partner of Greenoaks, said: “Discovering and developing new medicines is an optimisation challenge of almost infinite scale.

“Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines.

“We believe Demis, Max, and the Isomorphic team are building the future of AIled drug discovery and we are proud to partner with them on this essential mission.”

subscribe banner

Konstantine Buhler, partner at Sequoia Capital, added: “Isomorphic Labs is building foundational technology for the future of medicine.

“It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.”

Zoom, HSBC & BBC hit in Optimizely malware attack